Key Takeaways GILD leads HIV space with Biktarvy, Descovy and new PrEP drug Yeztugo driving momentum. GILD sees stronger 2025 HIV revenue growth and posts gains across liver disease and oncology.GILD outperforms on price performance while BMY faces legacy drug pressure and higher debt.Bristol Myers Squibb (BMY) and Gilead Sciences, Inc. (GILD) are leading biotechnology companies with broad, diverse portfolios and a global footprint.BMY boasts a strong portfolio with drugs for oncology, hematology, immunolog ...

WINNIPEG, Manitoba, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its third quarter 2025 financial results. Third Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended September 30, 2025 was $8,499 compared to $1,282,698 in the three months ended September 30, 2024. The vast majority of revenue recorded in the comparative quarter was relat ...

From high-yield pharma plays to growth-oriented compounders, these eight stocks offer something for every dividend investor.High-yield stocks receive all the attention, but the best dividend portfolios strike a balance between current income and long-term compounding. These eight stocks span multiple sectors and investment styles, from low-yield growth machines to high-yield income generators.Each stock offers a different reason to own it -- and together, they form the foundation of a diversified dividend s ...

Market Overview - U.S. stock futures halted trading on Friday due to a data center glitch, impacting trade in US Treasuries and crude oil [1] - The benchmark index tracking ETFs was trading higher, with the SPDR S&P 500 ETF Trust (SPY) up 0.30% at $681.70 and Invesco QQQ Trust ETF (QQQ) up 0.42% at $616.85 [3] Company Performance - Tilray Brands Inc. (TLRY) fell 14.93% in premarket trading after announcing a 1-for-10 reverse stock split, maintaining a weaker price trend [7] - Direct Digital Holdings Inc. (DRCT) dropped 12.06% after revealing a settlement agreement to issue up to 50 million Class A common shares [7] - SMX (Security Matters) PLC surged 74.43% after presenting its technology at a conference in Dubai, despite maintaining a weaker price trend [7] - Walmart Inc. (WMT) rose 0.31% on Black Friday, promising discounts and exclusive offers, and maintaining a stronger price trend [7][15] - Apple Inc. (AAPL) was up 0.36% on Black Friday, offering promotions and gift cards, while maintaining a stronger price trend [15] Economic Insights - The consumer debt level in the U.S. has reached $18.6 trillion, but the ratio of household debt to disposable income is near a 25-year low at just below 90% [10][11] - The consumer landscape is described as "bifurcated," with high-wage earners spending while lower-income consumers struggle [11] - The long-term economic outlook remains optimistic, with projections for improvement driven by AI-related capital expenditures and deregulation [12]

Core Insights - Zelluna has appointed Geir Christian Melen as the new Chief Financial Officer, effective January 1, 2026, succeeding Hans Vassgård Eid who will step down at the end of December 2025 [1][2][3] Company Overview - Zelluna ASA is a biotechnology company focused on developing allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for cancer treatment [4] - The company's lead program, ZI-MA4-1, targets the MAGE-A4 tumor antigen and is expected to enter clinical trials in 2026 [4] Leadership Transition - Geir Christian Melen has over seven years of experience with Zelluna as Finance Director and possesses a strong understanding of the company's TCR-NK platform and financial strategy [2][3] - The CEO of Zelluna, Namir Hassan, expressed appreciation for Hans Vassgård Eid's contributions, particularly in integrating Zelluna and Ultimovacs and preparing the company for clinical development [2]

Accessibility StatementSkip Navigation SYDNEY and SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a leading biotechnology company focused on cell-based immunotherapies, today announced a co-development collaboration to evaluate the combination of Imugene's oncolytic virus CF33-CD19 (onCARlytics) and JW's Carteyva®—a CD19- directed autologous CAR-T cell therapy—for patients with advanced solid tumors ...

Several biotech and life sciences companies posted notable gains in after-hours trading on Wednesday, November 26, reflecting investor interest despite a relatively quiet news cycle.Modular Medical, Inc. (MODD) shares surged in after-hours trading on November 26, climbing 11.51% to $0.4380. This rebound followed a modest decline of 1.80% at the close, where the stock ended at $0.3928. While no fresh news was released on Wednesday, investors may still be reacting to the company's November 17 announcement of ...

New York, New York--(Newsfile Corp. - November 27, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the "Class Period"), of the important January 16, 2026 lead plaintiff deadline.SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency f ...

Personalis ( PSNL ) is a liquid biopsy company that is initially targeting the MRD and drug research markets. While competition in these markets is fierce, Personalis is differentiated by its whole genome sequencing approach, which should benefit fromRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be achieved by identifying ...

Overview of Arrowhead Pharmaceuticals - Arrowhead Pharmaceuticals has made significant recent progress and accomplishments, particularly highlighted by the update on the Sarepta partnership [2] Future Expectations - Investors should anticipate further developments from Arrowhead as the company approaches the end of the year and into 2026 [2]